Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Mednet Member

Medical Oncology · Winship Cancer Institute of Emory University

Bortezomib and thalidomide cause the bulk of the neuropathy in myeloma patients worldwide, although thalidomide is rarely used in the U.S. because of more effective immune modulating drugs (IMiD's) available such as lenalidomide and pomalidomide. Pre-existing peripheral neuropathy is the biggest ris...